Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CUVITRU® safely and effectively. See full prescribing information for CUVITRU. CUVITRU®, Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 2016
Medication labelWhy this: Advisory · dailymed-other
CUVITRU is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Solution indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies1,2.
- generic_name
- immune globulin subcutaneous (human)
- product_names
- Immune Globulin Subcutaneous (Human)
- ndc
- 0944-2850, 0944-2850-02, 0944-2850-01, 0944-2850-04, 0944-2850-03, 0944-2850-06, 0944-2850-05, 0944-2850-08, 0944-2850-07, 0944-2850-10, 0944-2850-09
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en